688 related articles for article (PubMed ID: 32835657)
1. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
2. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
3. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
4. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
5. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
Cao L; Wan Q; Li F; Tang CE
BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
7. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
9. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
10. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y; Zhang J; Liu M; Huang Y; Yin L
J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
[TBL] [Abstract][Full Text] [Related]
11. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
12. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
13. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
[TBL] [Abstract][Full Text] [Related]
15. MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.
Zhang L; Liu XL; Yuan Z; Cui J; Zhang H
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4663-4672. PubMed ID: 31210292
[TBL] [Abstract][Full Text] [Related]
16. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
Mei J; Liu G; Li R; Xiao P; Yang D; Bai H; Hao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34821362
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
18. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
19. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
20. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
